BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gentile I, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 2016;25:557-72. [DOI: 10.1517/13543784.2016.1161023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Fenaux M, Lin X, Yokokawa F, Sweeney Z, Saunders O, Xie L, Lim SP, Uteng M, Uehara K, Warne R, Gang W, Jones C, Yendluri S, Gu H, Mansfield K, Boisclair J, Heimbach T, Catoire A, Bracken K, Weaver M, Moser H, Zhong W. Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk. Antimicrob Agents Chemother 2016;60:7077-85. [PMID: 27645237 DOI: 10.1128/AAC.01253-16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
2 Flick AC, Ding HX, Leverett CA, Fink SJ, O’donnell CJ. Synthetic Approaches to New Drugs Approved During 2016. J Med Chem 2018;61:7004-31. [DOI: 10.1021/acs.jmedchem.8b00260] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
3 Maraolo AE, Scotto R, Zappulo E, Pinchera B, Schiano Moriello N, Nappa S, Buonomo AR, Gentile I. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Rev Anti Infect Ther 2020;18:191-202. [PMID: 32011191 DOI: 10.1080/14787210.2020.1725473] [Reference Citation Analysis]
4 Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, De Pascalis S, Martini S, Macera M, Viceconte G, Tosone G, Buonomo AR, Borgia G, Coppola N. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort). Hepatol Int 2019;13:66-74. [DOI: 10.1007/s12072-018-9914-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
5 Yu W, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Coburn CA, Selyutin O, Chen L, Rokosz L, Agrawal S, Liu R, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. J Med Chem 2016;59:10228-43. [PMID: 27792320 DOI: 10.1021/acs.jmedchem.6b01234] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
6 Scotto R, Buonomo AR, De Pascalis S, Nerilli M, Pinchera B, Staiano L, Mercinelli S, Cattaneo L, Stanzione M, Stornaiuolo G, Martini S, Messina V, Coppola C, Coppola N, Gentile I. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results. Expert Rev Gastroenterol Hepatol 2021;15:1057-63. [PMID: 33573411 DOI: 10.1080/17474124.2021.1890029] [Reference Citation Analysis]
7 Gane E, Stedman C, Dole K, Chen J, Meyers CD, Wiedmann B, Zhang J, Raman P, Colvin RA. A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. ACS Infect Dis 2017;3:144-51. [PMID: 27788579 DOI: 10.1021/acsinfecdis.6b00138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Zhao F, Zhou N, Wang JL, Zhou H, Zou LQ, Zhong WX, He J, Zheng CJ, Yan SX, Wáng YXJ. Collagen deposition in the liver is strongly and positively associated with T1rho elongation while fat deposition is associated with T1rho shortening: an experimental study of methionine and choline-deficient (MCD) diet rat model. Quant Imaging Med Surg 2020;10:2307-21. [PMID: 33269229 DOI: 10.21037/qims-20-651] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother 2020;21:261-73. [PMID: 31914336 DOI: 10.1080/14656566.2019.1697674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025-2034. [PMID: 29703790 DOI: 10.1136/gutjnl-2018-316234] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 17.5] [Reference Citation Analysis]
11 Scotto R, Buonomo AR, Moriello NS, Maraolo AE, Zappulo E, Pinchera B, Gentile I, Borgia G. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. RRCT 2019;14:173-82. [DOI: 10.2174/1574887114666190306154650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
12 Borgia G, Scotto R, Buonomo AR. An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy. Expert Opin Investig Drugs 2019;28:395-7. [PMID: 30943797 DOI: 10.1080/13543784.2019.1602766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opin Investig Drugs 2018;27:243-50. [PMID: 29271672 DOI: 10.1080/13543784.2018.1420780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Koon CM, Zhang X, Chen W, Chu ES, San Lau CB, Wáng YX. Black blood T1rho MR imaging may diagnose early stage liver fibrosis: a proof-of-principle study with rat biliary duct ligation model. Quant Imaging Med Surg 2016;6:353-63. [PMID: 27709071 DOI: 10.21037/qims.2016.08.11] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
15 Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore) 2020;99:e18948. [PMID: 32028404 DOI: 10.1097/MD.0000000000018948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]